Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma

NCT02452281 | Withdrawn Phase 1

• 2 other identifiers: C-100-41HSC-MS-14-0070
• Study Type: interventional
• Target: N/A
• Locations: 1 country
• Sites: 1

Brief Summary

The purpose of this research study is to see if the combination of HSPPC-96 and ipilimumab is safe and effective in the treatment of advanced melanoma. HSPPC-96 is an investigational vaccine created from tissue from the patient's tumor. The vaccine is designed to capture the cancer's "fingerprint." Injection of the vaccine may cause the patient's immune system to recognize and attack any cells with the specific cancer fingerprint. Ipilimumab is a drug approved by the FDA for the treatment of metastatic melanoma that boosts immune response.

Conditions

Melanoma

Keywords

Therapeutically Unresectable; Stage III or Stage IV; Malignant Melanoma; Advanced Melanoma

Outcome Measures

Primary Outcomes (2)

• All enrolled patients who receive at least one dose of study drug (HSPPC-96) will be evaluated for safety. (adverse events)

  AEs will be coded by system organ class and preferred term using MedDRA. AEs will be summarized using descriptive statistics. Descriptive statistics will contain the number and percentage of patients who experience at least 1 AE, AEs related to study treatment, SAEs, SAEs related to study treatment, grade 3, 4 or 5 AEs, and grade 3, 4 or 5 AEs related to study treatment. In addition, the number and percentage of patients who discontinue treatment for any reason, including discontinuation due to an AE, will be provided together with the number and percentage of patients who die.

  2 years

• • To assess immunological response by surrogate markers of immune response and modulation of tumor cellular microenvironment

  All enrolled patients who receive at least one full cycle of treatment and have a baseline and at least one post treatment biological specimen available (tissue and/or blood) will be evaluated for immune response.

  2 years

Secondary Outcomes (2)

• Objective Response Rate (ORR)

  tumor evaluations every 12 weeks or until the date of first documented progression or death, whichever came first, assessed up to 24 months

• Progression Free Survival (PFS)

  tumor evaluations every 12 weeks or until the date of first documented progression or death, whichever came first, assessed up to 24 months

Study Arms (1)

ipilimumab + HSPPC-96

EXPERIMENTAL

* Ipilimumab is administered intravenously at a dose of 3 mg/kg one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles. * HSPPC-96 is administered at a dose of 25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab. * Length of Treatment: 4 cycles of ipilimumab and at least 6 cycles of HSPPC-96 up to 12 doses. * Booster doses of HSPCC-96 following 6 administrations on subsequent cycles will be administered every 21-23 days according to availability of vaccine.

Drug: ipilimumab; Drug: HSPPC-96

Interventions

ipilimumab DRUG

3 mg/kg, IV one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.

Also known as: Yervoy ®

ipilimumab + HSPPC-96

HSPPC-96 DRUG

25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab; for at least 6 cycles of HSPPC-96 up to 12 doses.

Also known as: heat shock protein-peptide complex 96; Prophage; Vitespen

ipilimumab + HSPPC-96

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Signed informed consent
• ≥ 18 years of age
• Stage III or Stage IV melanoma according to TNM staging criteria/AJCC version 7 determined by PET/MRI/CT scan
• ECOG score 0 or 1
• Life expectancy ≥6 months
• Candidate for surgical resection with viable melanoma tissue to ascertain ≥ 7 grams of viable cancer tissue (in aggregate), which is equivalent to a ≥ 2 cm lesion on CT/MRI or clinical examination
• Adequate cardiac function (≤ NYHA class II)
• Adequate bone marrow function, including: absolute granulocyte count (ANC) ≥ 1,500x106/L, absolute lymphocyte count (ALC) ≥ 500/mm3, platelets count ≥100,000 x 106/mm3. Adequate liver function including: serum glutamic oxaloacetic transaminases/aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x the upper limit of institutional normal (IULNs), bilirubin ≤ 1.5 mg/dL or 25 µmol/L (SI units). Adequate renal function: BUN and Serum creatinine of ≤ 1.5 mg/dL or 130 µmol/L (SI units)
• Female subjects of childbearing potential and fertile males must agree to use adequate contraception during the course of the study. Adequate contraception includes condoms with contraceptive foam; oral, implantable or injectable contraceptives; contraceptive patch; intrauterine device; diaphragm with spermicidal gel; or a sexual partner who is surgically sterilized or postmenopausal.
• Histologically and clinically confirmed Stage III and/or Stage IV malignant melanoma according to TNM Staging Criteria/AJCC version 7 confirmed by PET/CT scan
• Measurable disease for target lesion clinical and radiological monitoring
• ECOG score 0 or 1
• Adequate cardiac function (≤ NYHA class II)
• Adequate bone marrow function, liver, and renal function
• ≥ 6 doses of vaccine for clinical use

You may not qualify if:

• Primary mucosal or primary ocular melanomas
• Other malignancies treated within the last five years, except in situ cervix carcinoma or non-melanoma skin cancer
• Primary or secondary immunodeficiency (including immunosuppressive disease, or systemic use of corticosteroids or other immunosuppressive medications)
• Patients with history of HIV1 and 2, HTLV-1, HBV or active HCV.
• Patients with history of connective tissue disorders
• Prior ipilimumab or melanoma vaccine therapy
• Prior therapy with IL-2
• Prior chemotherapy, small molecule targeted therapy, interferon within 3 months prior to enrollment
• Prior investigational products administration within 4 weeks prior to enrollment
• Prior splenectomy
• Symptomatic CNS metastases or spinal cord compression
• Uncontrolled infection or other serious medical illnesses
• Any medical conditions that, in the opinion of the investigator, would preclude use of ipilimumab, including ipilimumab hypersensitivity
• Women who are pregnant or breast-feeding
• Concurrent participation in investigational trials

Sponsors & Collaborators

• Rabih Said: lead
• Agenus Inc.: collaborator

Study Sites (1)

UTHealth Memorial Hermann Cancer Center

Houston, Texas, 77030, United States

Location

MeSH Terms

Conditions

Melanoma

Interventions

Ipilimumab; vitespin

Condition Hierarchy (Ancestors)

Neuroendocrine Tumors; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Nerve Tissue; Nevi and Melanomas; Skin Neoplasms; Neoplasms by Site; Skin Diseases; Skin and Connective Tissue Diseases

Intervention Hierarchy (Ancestors)

Antibodies, Monoclonal, Humanized; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins

Study Officials

• Rabih Said, MD, MPH

  The University of Texas Health Science Center, Houston

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Assistant Professor, Department of Internal Medicine, Division of Oncology

Study Record Dates

• First Submitted: May 13, 2015
• First Posted: May 22, 2015
• Study Start: December 1, 2015
• Primary Completion: December 1, 2018
• Study Completion: December 1, 2018
• Last Updated: January 25, 2016

Record last verified: 2016-01

Locations

US (1)